June 20, 2017 — The U.S.
Intra-Aortic Balloon Pumps (IABP)
-
-
Teleflex Inc. announced the worldwide recall of Arrow International intra-aortic balloon catheter kits and percutaneous insertion kits.
-
Datascope Corp./Maquet initiated a voluntary worldwide field correction of some of its intra-aortic balloon pumps (IABPs) due to a potential mechanical failure of the fan assembly associated with...
-
Percutaneous ventricular assist (pVAD) devices offer more hemodynamic support than the 40-year-old gold standard of intra-aortic balloon pumps (IABPs), but their cost and complexity has...
The Datascope CS300 IABP console.
News | Hemodynamic Support Devices | June 20, 2017
June 20, 2017 — The U.S. Food and Drug Administration (FDA) said Maquet/Datascope is voluntarily performing a...
Technology | Intra-Aortic Balloon Pumps (IABP) | May 02, 2017
May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc. AC3 Optimus...
News | Intra-Aortic Balloon Pumps (IABP) | January 03, 2017 | Dave Fornell
January 3, 2017 — The Impella CP heart pump (Abiomed) demonstrated no improvement in mortality for patients with...
News | Intra-Aortic Balloon Pumps (IABP) | March 11, 2016
March 11, 2016 — Teleflex Inc. announced the worldwide recall of Arrow International...
Feature | June 01, 2015
June 1, 2015 — Maquet Getinge Group announced the publication of a manuscript describing the exploration of the...
News | April 09, 2015
April 9, 2015 — Maquet Cardiovascular USA announced publication of a manuscript comparing the clinical and economic...
Feature | May 12, 2014
May 12, 2014 — Datascope Corp./Maquet initiated a voluntary worldwide field correction of some of its intra-aortic...
Procyrion Aortix is a catheter-deployed pVAD intended for long-term use in the treatment of chronic heart failure.
Feature | March 18, 2014 | Dave Fornell
P...
News | October 01, 2013
October 1, 2013 — Sunshine Heart Inc. has launched a website dedicated to providing information to patients...
Abiomed introduced the Impella CP (Cardiac Power) pVAD in 2012, which delivers up to 4 lpm of flow.
Feature | May 13, 2013 | Dave Fornell
Since the 1970s,...
Blog | December 07, 2012
Two key news items in September made me think about the future direction of hemodynamic support, and that ...
Feature | December 07, 2012 | Dave Fornell
Two key news items in September made me think about the future direction of hemodynamic support, and that...
Feature | November 08, 2012
November 8, 2012 — A U.S. Food and Drug Administration (FDA) advisory committee is meeting Dec. 5 to discuss how to...
Technology | October 30, 2012
October 30, 2012 — Maquet Cardiovascular received 510(k) clearance from the U.S. Food and Drug Administration (FDA)...
The Impella percutaneous left ventricular assist devices (pLVAD) is an emerging option for partial or total circulatory support. In several randomized, controlled trials, pLVAD therapy demonstrated a better hemodynamic profile compared to IABP, although this did not translate into improved 30-day survival with use of pLVAD therapy.
Feature | September 11, 2012
September 11, 2012 — Primary results from an ongoing trial by Maquet Cardiovascular using...
